CDT Equity Partners with Sarborg on 1,700 Rare Disease Signatures Database
CDT Equity Inc. has partnered with Sarborg to map its asset portfolio, including combination therapies, against a newly curated database of approximately 1,700 rare disease signatures. CDT, which holds a 20% equity stake in Sarborg, aims to bolster its IP position and explore external commercialization opportunities.
1. Sarborg Expands AI Signature Database
Sarborg Limited has curated a rare disease signature database containing approximately 1,700 unique profiles, building on its existing library of over 1,600 diseases and prior agrochemical and bacterial datasets. These machine-interpretable biological signatures enable rapid analysis of disease relationships and identification of potential therapeutic targets.
2. CDT Collaboration and Equity Stake
CDT Equity Inc. has entered a new collaboration to map its asset portfolio, including certain combination therapies, against Sarborg’s expanded rare disease database. The company holds a 20% equity stake in Sarborg and will leverage the platform to strengthen its intellectual property position based on mapping outcomes.
3. Strategic Commercialization Prospects
By integrating rare disease signatures with CDT’s therapeutic assets, the company intends to uncover novel repositioning and licensing opportunities. The collaboration is designed to accelerate preclinical research workflows and create external partnership avenues for asset monetization.